BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 24468312)

  • 1. Chemotherapeutic advancements in peripheral T-cell lymphoma.
    Reddy NM; Evens AM
    Semin Hematol; 2014 Jan; 51(1):17-24. PubMed ID: 24468312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas.
    Zinzani PL; Bonthapally V; Huebner D; Lutes R; Chi A; Pileri S
    Crit Rev Oncol Hematol; 2016 Mar; 99():214-27. PubMed ID: 26811013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma.
    Rogers AM; Brammer JE
    Curr Hematol Malig Rep; 2020 Aug; 15(4):316-332. PubMed ID: 32529515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of peripheral T-cell lymphoma: are we data driven or driving the data?
    Lunning MA; Horwitz S
    Curr Treat Options Oncol; 2013 Jun; 14(2):212-23. PubMed ID: 23568456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Peripheral T-Cell Lymphoma: Many Shades of Gray.
    Lunning MA
    Oncology (Williston Park); 2015 Aug; 29(8):545-50. PubMed ID: 26281838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management.
    Zain JM
    Am J Hematol; 2019 Aug; 94(8):929-946. PubMed ID: 31119775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
    Coiffier B; Federico M; Caballero D; Dearden C; Morschhauser F; Jäger U; Trümper L; Zucca E; Gomes da Silva M; Pettengell R; Weidmann E; d'Amore F; Tilly H; Zinzani PL
    Cancer Treat Rev; 2014 Oct; 40(9):1080-8. PubMed ID: 25199959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of high-dose therapy in peripheral T-cell lymphomas.
    Reimer P; Rüdiger T; Wilhelm M
    Clin Lymphoma Myeloma; 2006 Mar; 6(5):373-9. PubMed ID: 16640812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral T-cell lymphoma, NOS, and anaplastic large cell lymphoma.
    Beaven AW; Diehl LF
    Hematology Am Soc Hematol Educ Program; 2015; 2015():550-8. PubMed ID: 26637771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Treatment of Peripheral T-cell Lymphoma.
    Stuver R; Epstein-Peterson ZD; Johnson WT; Khan N; Lewis N; Moskowitz AJ; Sauter CS; Horwitz S
    Oncology (Williston Park); 2022 May; 36(5):293-305. PubMed ID: 35576176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
    Iyer SP; Foss FF
    Oncologist; 2015 Sep; 20(9):1084-91. PubMed ID: 26099743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New perspectives in the therapeutic approach of peripheral T-cell lymphoma.
    Gisselbrecht C; Sibon D
    Curr Opin Oncol; 2018 Sep; 30(5):285-291. PubMed ID: 30096094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.
    Gkotzamanidou M; Papadimitriou CA
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment.
    Merdin A; İskender D; Ulu BU; Doğan M; Çakar MK; Dal MS; Altuntaş F
    Medicine (Baltimore); 2019 Jul; 98(30):e16482. PubMed ID: 31348254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment approaches in relapsed or refractory peripheral T-cell lymphomas.
    Foster C; Kuruvilla J
    F1000Res; 2020; 9():. PubMed ID: 32934797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas.
    Shustov A
    Best Pract Res Clin Haematol; 2013 Mar; 26(1):89-99. PubMed ID: 23768643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma.
    Marchi E; Raufi AG; O'Connor OA
    Hematol Oncol Clin North Am; 2017 Apr; 31(2):359-375. PubMed ID: 28340883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Peripheral T-cell Lymphomas and the Role of Transplant.
    Foley NC; Mehta-Shah N
    Curr Oncol Rep; 2022 Nov; 24(11):1489-1499. PubMed ID: 35947286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stem cell transplantation for peripheral T-cell lymphomas.
    Jantunen E; D'Amore F
    Leuk Lymphoma; 2004 Mar; 45(3):441-6. PubMed ID: 15160904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.